Ulrich Pecks: Personalized Approaches to VTE Prevention in Pregnant Women with Inherited Thrombophilia
Ulrich Pecks, Head of Obstetrics and Maternal Health and Fetal Development at Universitätsklinikum Würzburg, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“In addition to our recent publication on VTE prophylaxis after CS in JPM we are proud of our accepted review in Archives which provides an overview of guidelines for hereditary thrombophilia in pregnancy.
Key points:
- Pregnant women with inherited thrombophilia have a significantly higher risk of venous thromboembolism (VTE), up to approximately 40-fold depending on type and history.
Risk classification:
- Low risk: e.g., heterozygous factor V Leiden or prothrombin mutation
- High risk: e.g., homozygous mutations, combined thrombophilia, severe antithrombin/protein C/S deficiency
Guidelines vary:
International recommendations for thromboprophylaxis differ widely – no universal standard.
Use of prophylaxis (heparin):
Generally recommended for high-risk thrombophilia (during pregnancy and 6 weeks postpartum).
For low-risk, only if additional risk factors or positive family history are present.
Limited evidence:
There is no strong evidence from randomized controlled trials proving that pharmacological prophylaxis significantly reduces VTE risk.
Risk–benefit balance:
Prophylaxis carries risks (e.g., bleeding), and VTE risk may be overestimated – possible overtreatment.
Individualized decision-making:
Management should be case-by-case, considering individual risk profile, history, and patient preference.
Bottom line:
Although VTE risk is increased in pregnant women with thrombophilia, inconsistent guidelines and limited evidence mean that prophylaxis decisions must be individualized.”
Title: Recommendations from guidelines for the prevention of venous thromboembolism in pregnant women with inherited thrombophilia
Authors: Werner Rath, Panagiotis Tsikouras, Ulrich Pecks
Read the Full Article on Springer.

Stay updated on all scientific advances with Hemostasis Today.
-
Apr 15, 2026, 04:06Brenda Pleasant: Insights from the HFA Symposium on Hemophilia Care
-
Apr 15, 2026, 03:43Lexy Halloran: Addressing Diagnostic Inequities in Women with Chronic Conditions
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
-
Apr 14, 2026, 16:56Saskia Middeldorp: Key Takeaways from the 2026 ACC/AHA Guideline on Acute PE